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Abstract 
Over the centuries, microbial secondary metabolites have played a central role in the treatment of human 
diseases and have revolutionised the pharmaceutical industry. With the increasing number of sequenced 
microbial genomes revealing a plethora of novel biosynthetic genes, natural product drug discovery is 
entering an exciting second golden age. Here, we provide a concise overview as an introductory guide to the 
main methods employed to unlock or up-regulate these so called ‘cryptic’, ‘silent’ and ‘orphan’ gene 
clusters, and increase the production of the encoded natural product. With a predominant focus on bacterial 
natural products we will discuss the importance of the bioinformatics approach for genome mining, the use 
of first different and simple culturing techniques and then the application of genetic engineering to unlock 
the microbial treasure trove. 
 
1. Introduction 
For millennia, natural products have been the cornerstone of medicine: for example, the ancient Egyptians 
utilised the antibiotic properties of honey to aid wound healing.
1
 It was not until the beginning of the last 
century, however, that our knowledge and understanding of science and nature enabled us to look at these 
health conferring natural products at a molecular level and identify the bioactive compounds that reside 
within them. The epiphany of modern natural product chemistry is famously exemplified by Alexander 
Fleming’s seminal discovery that Penicillium rubens was capable of producing a substance with antibiotic 
properties.
 2
 The structure of this bioactive compound, penicillin (1), was theorised by Ernst Boris Chain
3
 
and later confirmed by Dorothy Hodgkin.
 4 
This notable observation resulted in an intense period of pursuit 
 2 
of bioactive microbial secondary metabolites. As a result, a wealth of medicinally-relevant compounds have 
been revealed with many notable examples including the antifungal agent nystatin (2), the antibiotics 
erythromycin (3) and vancomycin (4), the cholesterol lowering drug lovastatin (5) and the 
immunosuppressant rapamycin (6). 
 
Figure 1. Penicillin (1), nystatin (2), erythromycin (3), vancomycin (4), lovastatin (5) and 
rapamycin (6). 
Despite the proven success of natural products as drugs, many pharmaceutical companies abandoned their 
natural product drug discovery programmes due in part to high rates of re-discovery of known compounds 
and the difficulty of accessing synthetic analogues. They favoured instead the generation of large libraries of 
synthetic compounds that were more compatible with high-throughput screening.
5
 Bacterial-based natural 
product discovery programmes have traditionally employed the fermentation of such microbes in a series of 
media and then the screening of extracts for any promising bioactives that are produced. However, as we 
moved into the 21
st
 century, the advent of genomic sequencing has initiated a second golden age of drug 
discovery as gene clusters encoding the assembly of previously undiscovered natural products could be 
mined out from the massive number of published genomes. Though considerable research has been devoted 
to unlocking cryptic pathways in fungi, as overviewed in a number of reviews,
6-11
 the unlocking of bacterial 
pathways is still in its infancy and represents an exciting opportunity. A growing number of different 
approaches, with the aim of providing a more global solution to unlocking bacterial cryptic pathways, have 
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been published in recent years, including studies with a focus on unlocking the treasures of the 
megasynthases through increasing transcription levels and “reviving dead” genes.74,76  Streptomycetaceae are 
known to be a prolific source of bioactive compounds: so far over 200 drugs based on products isolated from 
these microorganisms are in clinical trials or FDA approved
12
 and have been used for treating infections, 
cancer circulation and immune system disorders and many other disease states. When the genome sequence 
of the archetypal Streptomycetaceae Streptomyces coelicolor A3(2) was published in 2002,
13
 the sequence 
data revealed, along with the known secondary metabolite clusters, a plethora of genes encoding for as yet 
unobserved molecules, including nonribosomal peptides and polyketides.
13,14
 Secondary metabolite clusters 
that produce no noticeable quantities of metabolite have been termed “silent” and it is unknown what 
conditions trigger their biosynthesis; further, there are orphan clusters, with as yet undiscovered products.
15
 
The emerging area of triggering the production of cryptic metabolites in microorganisms was overviewed by 
Hertweck in 2009.
16
 With more than 1800 bacterial genomes now sequenced
17
 there is the potential for the 
discovery of new structural classes by simply reading the genome, then selectively pursuing these previously 
uninvestigated compounds. Using this approach, new drug leads with novel modes of action may be 
revealed. 
This highlight aims to provide an easy to utilise glossary of approaches that can be applied by natural 
product scientists to elicit the production of cryptic natural products and thereby enable their purification and 
identification. Although there is substantial overlap and complementarity between approaches, we group 
such methods into two main categories, ‘physiological triggers’ and ‘metabolic engineering’ via genetic 
manipulation. We start by looking at the prediction of cryptic gene clusters by in silico genome mining. Then 
we examine the traditional approaches of OSMAC (One Strain Many Compounds), where different culturing 
conditions are used to trigger and optimise compound production; co-culturing is then explored before 
looking at employment of chemical elicitors. Leading on from that, the genetic methods for unlocking or 
upregulating biosynthetic pathways, including promoter and regulator manipulation, heterologous expression 
and epigenetic modification will be discussed. 
 
2. Reading the genome 
The massive acceleration in the development of sequencing technologies over the past decade has resulted in 
easy and affordable access to bacterial genomes. Streptomycetaceae, a large family of soil dwelling bacteria, 
are responsible for producing over 80% of all known antibiotics
18
. The first Streptomyces genome (that of S. 
coelicolor A3(2)) was published in the 2002
13
 and the availability of its complete annotated sequence 
allowed the prediction and characterization of pathways involved in the production of at least 17 chemically 
distinct classes of bioactive compounds as reviewed by Challis
19
.
 
Completely assembled and annotated 
genome sequences for over 65 Streptomycetes and hundreds of bacterial species demonstrated that more than 
50% are likely to have one or more gene cluster involved in the biosynthesis of polyketides or non-ribosomal 
peptides.
20
 Additionally, a recent review by Hertweck highlights the biosynthetic potential showcased in the 
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sequence data of anaerobic microbes.
21
 Across bacteria, there clearly exists a huge treasure trove of as yet 
undiscovered medicines that remains to be unlocked. The rise of metagenomic sequencing projects has 
further expanded the dataset. Considering the vast number of data available for mining, advanced gene 
analysis tools such as antiSMASH
22
, CLUSTSCAN
23
, SBSPKS
24
 and NP searcher
25
 have made genome 
reading more accessible to increasing numbers of researchers with an interest in natural products science. 
Frequently in microbial systems, genes encoding a particular biosynthetic pathway cluster together 
oftentimes with specific regulatory elements and genes encoding resistance mechanisms present in the same 
cluster. Nonetheless, it is worth to consider genes that cluster in an unusual way as they can suggest novel 
structural types of natural products.
 20
 Much about the structure of the product encoded by the biosynthetic 
cluster (cryptic or otherwise) may be deduced by reading the genome. By comparing the genes of interest to 
characterized homologues it is often possible to accurately predict the biogenesis of the product, for example 
whether it contains a polyketide component and what the length, oxidation state and dehydration level of the 
nascent polyketide chain is. Furthermore, it is often possible to speculate upon substrate specificity and 
stereoselectivity, particularly for non-ribosomal peptide synthetases (Figure 2).
26, 27
 
 
Figure 2. Genome Mining. gDNA is sequenced and read (1). The raw sequence data is annotated 
based upon sequence homology to existing data, identifying ORF (2). Clustered genes can be 
extracted and identified from the genome annotation and analysed further by specialised 
bioinformatics software (3) which allows prediction of substrate (4). The often linear nature of their 
assembly then allows for prediction of the final chemical structure (5). If the structure is accurately 
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predicted, substrate specificity may be deduced enabling informed media preparation and 
fermentation (6).  
 
  
In 1999, Stachelhaus et al. demonstrated a correlation between the essential amino acid residues in 
adenylation domains of non-ribosomal peptide synthetases (NRPSs) and substrate specificity.
28
 Almost at the 
same time, Challis et al. established a method for predicting the substrate specificity of adenylation domains, 
responsible for selecting and activating specific amino acids based on the genome sequence of NRPSs.
29
 
Polyketide and non-ribosomal peptide natural products, particularly those of canonical construction, provide 
the best exemplifications of prediction of these biosynthetic systems. The modular nature of higher 
polyketide synthases (PKSs) and NRPs combined with the current understanding of their substrate 
specificity allows for the logical deduction as to which chemical building blocks are incorporated and in 
which order. Enzymatic tailoring of the assembly line, such as glycosylation methylation and oxidation, may 
also be postulated from the genome sequence. Analysis of the genome of the
 
strict anaerobe, Clostridium 
beijerinckii, (NCIMB 8052, JGI project ID 3634512), used extensively in the industrial manufacture of 
solvents including ethanol, acetone and butanol indicated the presence of a series of biosynthetic clusters 
although no secondary metabolites had been reported from this organism. Hertweck and coworkers sought to 
investigate this further, and as the industrially utilised strain, whose genome sequence they had analysed, 
was not readily obtainable, instead they investigated a related C. beijerinckii strain (HKI0724) from the HKI 
strain collection. In contrast to other C. beijerinckii strains reported in the literature, fermentation of this 
organism resulted in a purple-red broth. Isolation and characterisation of the pigment revealed it to be a 
potent polyphenolic antibiotic of polyketide origin, but with a non-canonical folding pattern.  This first 
polyketide to be reported to be derived from an anaerobic bacterium has been named clostrubin (7).
30
 
 
Figure 3. Structure of clostrubin (7). 
30
 
Recent new advances have been pioneered by Nguyen and colleagues who have developed approaches to 
link LC-MS/MS metabolomic profiles with gene clusters responsible for the production of secondary 
metabolites;
31
 the advantage of this approach is that it can be extended to organisms with unsequenced 
genomes based on the fact that “gene cluster families” involved in natural products biosynthesis can be 
directly linked to known “molecular families” by simply reading the mass spectral fragmentation pattern. 
The in silico prediction of metabolites and gene clusters responsible for their production represents a very 
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powerful tool for the identification of pathways encoding secondary metabolites and can enable the chemist 
to prioritize and focus resource toward the isolation and identification of novel natural products. 
 
3. Altering of Chemical and Physical Conditions 
3.1 OSMAC 
Varying culturing conditions is a frequently used approach to elevate titres of compound production and to 
encourage the production of a wider range of the natural products from a microorganism. The approach 
termed OSMAC (One Strain MAny Compounds)
32
 by Bode and co-workers (and initially explored by Hans 
Zahner),
33
 refers to the fact that a single bacterial strain is capable of producing a diverse array of structurally 
different compounds. A microorganism never produces the entire arsenal of compounds at the same time 
under one set of environmental conditions, this would be energetically and metabolically costly; rather, the 
biosynthesis of such metabolites is strictly controlled and depends on various internal and external cues. 
Each compound is produced only when needed, ensuring a competitive advantage when environmental 
conditions change. Consequently, by varying culturing conditions, it can be possible to induce or optimise 
the production of secondary metabolites. There have been many successful examples of the application of 
the OSMAC approach to enable the production of previously unknown natural products from microbial 
strains. Using such an approach, Knappe et al. found a new lasso peptide, capistruin (8), from the 
Burkholderia thailandensis E264 strain.
34
 Initially, culturing in M9 minimal medium at 37 ˚C, trace amounts 
of the compound were observed. Different culturing conditions were explored and employed demonstrating 
that the production of capistruin could be increased approximately 300-fold when culturing in M20 medium 
at 42˚C. In 2011, Rateb et al. explored the potential of natural products biosynthesis of the Streptomyces 
strain C34 isolated from a hyper-arid desert soil.
35
 When C34 was cultured in ISP2 medium, two novel 
ansamycin compounds, chaxamycins A (9) and B (10), were found; however when the glucose in ISP2 was 
replaced with glycerol, two other novel compounds, chaxamycins C (11) and D (12) were produced instead. 
From 3 L culture broth, 75 mg chaxamycin A, 28 mg chaxamycin B, 2 mg chaxamycin C and 7 mg 
chaxamycin D could be purified. Following on from these results, they explored eight further media 
obtaining a series of diverse metabolic profiles. Three new compounds from the rare class of 22-membered 
macrolactone polyketides, chaxalactins A-C (13-15) were detected from a defined medium which also 
contained glycerol as the main carbon source, and 19 mg (chaxalactin A), 7 mg (chaxalactin B) and 11 mg 
(chaxalactin C) pure compounds were obtained from a 3 L culture. 
36
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Figure 4. Lasso peptide, capistruin (8). 
The OSMAC approach is not targeted to the activation of a specific cryptic gene cluster, but to the 
systematic alteration of readily accessible culturing parameters including medium components (salts, amino 
acids, carbon source), pH, culture aeration (including the type of culture vessel used) and temperature of 
growth. This makes the OSMAC approach an accessible, versatile, inexpensive and relatively simple tool to 
use. Variations in the entire metabolic profile can be observed when a chemical component is added/depleted 
or a physical parameter changed within the culturing system. In a similar vein, increasing precursor/substrate 
supply can have a profound impact upon production levels.   The examples that we describe in this paragraph 
demonstrate that different carbon sources, nutrient availability and growth temperature are capable of 
influencing the onset of secondary metabolites production in bacteria.  
 
3. 2 Genome-informed culturing to coerce the production of selected natural products  
 
Insights into the structural and physico-chemical features of novel cryptic secondary metabolites can lead to 
the informed exploration of specific culturing conditions in order to enable production of compounds 
predicted through genome reading. Genome scanning or sequencing followed by in silico gene mining is a 
powerful tool for the identification of genes encoding enzymes involved in the biosynthesis of natural 
product. Genome analysis enables canonical biosynthetic assembly lines to be read and their products to be 
postulated with a degree of confidence. By reading the genome of S. coelicolor Challis and Ravel were able 
to propose a tripeptide product for one of the 14 remaining cryptic secondary metabolite clusters of S. 
coelicolor.
37, 38
 Their postulation as to the structure of the natural product led them to speculate that the 
compound might be an iron siderophore. Based on this hypothesis, an appropriate growth medium depleted 
in iron, was rationally selected to induce the compound’s biosynthesis. This informed approach enabled 
sufficiently enhanced levels of production of coelichelin (16) for the compound to be isolated and 
characterised. The final structure was, however, found to be a tetrapeptide, illustrating existing flaws in the 
prediction of compound structure from sequence data when the biosynthetic machinery is used iteratively or 
skips modules.
37
 By analysing the genome of Streptomyces aizunensis NRRL B-11277, McAlpine et al. were 
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able to identify 11 gene clusters encoding natural products. Detailed bioinformatics analysis of one of these 
clusters enabled prediction that the strain could be capable of the production of a linear polyene polyketide 
with a predicted mass of approximately 1297 Da; culturing media were screened and optimised for the 
production of this particular polyene (now known to be antifungal agent ECO-02301 (17)), and an 
understanding of the anticipated lipophilicity of the predicted molecule informed steps toward its isolation.
39
 
A similar approach may be employed with NRPs; as discussed above the amino acid composition of the 
compound can be predicted from the nucleotide sequence of the cluster encoding for the NRPSs.
28, 29
 Using 
this approach, Gross et al. were able to predict and isolate orfamide A (18) from Pseudomonas fluorescens 
Pf-5. Amino acidic sequence alignment showed that the compound was related to lipopeptides of the 
amphisin and viscosin classes, in particular with a side chain connected to a leucine residue (Leu1). Based on 
the Gerwick’s Genomisotopic approach, a tool developed to assist genome mining, the labeled amino acid 
predicted as precursor was used thus enabling the identification and isolation of orfamide A (17).
40
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Figure 5. Chaxamycins A, B, C, D (9-12)
35
 chaxalactins A-C (13-15)
36
 coelichelin (16)
 37
, ECO-02301 (17)
 
39
 and orfamide A (18)
 40
. 
 
3.3 Co-Culturing 
Co-culturing provides a further straight-forward yet effective approach to elicit natural product generation by 
simply growing a microorganism together with one or more additional microbial strains. Interspecies cross 
talk can often trigger the production of specific bioactive compounds for defensive purposes (Figure 6). In 
nature, bacteria live in complex, multi-species communities; unleashing the full biosynthetic potential of a 
bacterium in the laboratory is likely to rely upon mimicking the dynamic natural environment. There are 
many published examples in which a specific natural product’s generation has been induced or increased 
with the aid of co-culturing techniques. For example a series of co-culturing experiments with 16 marine-
derived bacterial strains, each co-cultured with one of the three terrestrial challengers, Staphylococous 
aureus, Escherichia coli and Pseudomonas aeruginosa, was reported by Mearns-Spragg et al..
41
 The 
challenger strain was added to the fermentation, constrained within dialysis tubing, allowing interspecies 
cross talk through the diffusion of small molecules. In these experiments, 12 of the 16 marine derived strains 
demonstrated enhanced antibiotic activity against either E. coli, S. aureus or P. aeruginosa, with some of the 
most striking results arising from co-culture with S. aureus 6871. Six of the marine derived strains, co-
cultured with this challenger, produced supernatants with increased antibiotic activity. One marine strain 
(Mbbc1122) showed not only increased levels of activity, but also increased spectral activity. The 
supernatant of Mbbc1122 co-cultured with S. aureus 6871 was active against both the Gram-negative E. coli 
and the Gram-positive S. aureus whereas the control was only active against E. coli. This indicates that the 
co-culturing approach positively impacted upon both natural product titre as well as chemical diversity 
produced by the strain. The study also demonstrated that in many cases a living challenger was not required, 
with heat killed cells being as effective in eliciting antibiotic production. A later study also demonstrated that 
the supernatant of an unspecified bacterial fermentation could be used to induce antibiotic production in a 
number of marine derived microbes.
42
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Figure 6. Co-culturing. Chemical signals produced by one bacterium (orange) are capable of inducing the 
biosynthesis of chemicals in a second bacterium (pink).
 
 
Bacterial co-culturing has enabled the production and discovery of a number of new biologically active 
compounds. In 2001, growth of an unidentified Gram-negative bacterium CNJ-328 with a marine derived 
fungus, belonging to the Pestalotia spp., yielded a new chlorinated benzophenone, pestalone (19).
43
 In 2003, 
co-culture of marine microbes C-148 and CF-20 with Vibrio anguillarum resulted in the production of a 
number of diketopiperazine (20) natural products with antibiotic properties, four of which had not been 
previously identified in nature.
44
 Streptomyces endus S-522 is another example of a strain that, when cultured 
in the presence of the mycolic acid producer Tsukamurella pulmonis, was found to generate the novel 
secondary metabolite alchivemycin A (21).
45
 In the same study, T. pulmonis was also shown to induce red 
pigment production in Streptomyces lividans.
45 
Co-culturing provides a useful approach not only for eliciting the production of novel natural products so 
that they may be assigned to orphan gene clusters, but it can also be used for the induction of silent natural 
products the production titres of which may be too low to detect. The production of the diterpene 
lobocompactol (22), produced by Streptomyces cinnabarinus PK209, was investigated in co-culture with 
Alteromonas sp.KNS-16, a lobocompactol-resistant strain,
46
 and it was found that the production titres of this 
compound were increased 10-fold. The authors demonstrated that the amount of challenger inoculum is an 
important factor to consider when performing co-culture experiments. Although all levels of challenger 
inoculum resulted in production, it was recognised that an optimum inoculum strength existed for the 
production of lobocompactol (22) with an inoculum of 10
5
 cells of challenger resulting in peak production 
levels (25% greater than when a 10
6 
inoculum was used, and approximately 300% greater than 10
4
 
innoculum was used).
46  
 
The much studied model actinomycete S. coelicolor has also been subjected to co-culturing studies, and it 
has been demonstrated that Myxococcus xanthus induces the overproduction of actinorhodin (23) by 20-
fold.
47
 In elegant research on S. coelicolor by Dorrestein and coworkers, employing nanospray desorption 
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electrospray ionisation (NanoDESI) and matrix-assisted desorption ionisation time of flight (MALDI-TOF) 
imaging spectroscopy, the researchers were able to capture a global overview of the chemical cross talk of 
this model organism as it interacted with five other actinomycetes.
48
 The five different interactions revealed 
227 compounds associated with S. coelicolor, with only 50% of these being known S. coelicolor metabolites. 
The newly associated S. coelicolor compounds included a number of novel acyl-desferrioxamines (24) which 
had previously not been observed. Strikingly it was demonstrated that there was huge variation in the 
portfolio of compounds produced by S. coelicolor as it interacted with the different actinomycetes, 
demonstrating that such responses are extremely specific. The revelation of the diversity of the chemical 
landscape, the incredible dynamics of these systems and the rich series of new compounds indicates that 
interspecies cross-talk and co-culturing will be a very valuable avenue in the search for new natural products.  
 
  
Figure 7. Pestalone (19)
 43
, diketopiperazine (20)
 44
, alchivemycin A (21)
 45
, lobocompactol (22)
46
, 
actinorhodin (23) 
47
 and acyl-desferrioxamines (24)
48
. 
3.4 HDAC Inhibitors 
Histone deacetylases (HDACs) are a large and ubiquitous family of proteins that play an essential role in 
modulating gene expression through deacetylation of histone proteins.
49
 Found in all domains of life,
50
 
HDACs act to make regulatory genetic elements more or less accessible through the deacetylation of histone 
proteins which pack the DNA. Through modifying accessibility to the gene, gene transcription is 
controlled.
49
 Consequently, HDAC inhibitors can have a stimulatory or inhibitory effect on the expression of 
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the corresponding genes.
51
 There have been many successful examples of the use of HDAC inhibitors to 
awake cryptic biosynthetic clusters in fungi.
52,53
 Cichewicz reviews this area of fungal epigenome 
manipulation, in which he is a key player.
54
 Following this pioneering work in fungi, researchers have 
recently started to apply the use of HDAC inhibitors to bacteria.
49
 Looking solely at the effect of HDAC 
inhibitors on the production of actinorhodin (ACT, 23) and the RED pigment (acknowledged elsewhere to 
comprise of both undecylprodigiosin (25) and streptorubin B (26) 
49b
),  Moore et al. screened a range of 
HDAC inhibitors to identify a number of compounds which elicit production of either one or both of these 
RED or ACT pigments.
49
 Elicitors included sodium butyrate (27), valproic acid (28), apicidin (29) and 
quercetin (30) (Table 1). The use of sodium butyrate as a chemical elicitor was further validated when 
applied to Streptomyces KY5 cultures, leading to a significant increase of antifungal activity.
49
  
 
Figure 8． Undecylprodigiosin (25) and streptorubin B (26). 
Table 1. Properties and effects of HDAC inhibitors on antibiotic production by S. coelicolor.
49 
HDAC inhibitor Effective concentration Stock solution Effects 
Sodium butyrate (27) 
 
25 mM 100 mM in water Strong induction of ACT 
(23), slight induction of 
the RED pigment  
Valproic acid (28) 1 mM 10 mM in DMSO Strong induction of ACT 
(25) 
Apicidin (29) 1 mM 1 mg/mL in 50% DMSO Strong induction of ACT 
(23) 
 Quercetin (30) 10 mM 100 mM in 5% DMSO Slight induction of ACT 
(23) 
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Figure 9． The HDAC inhibitors, sodium butyrate (27), valproic acid (28), apicidin (29), quercetin (30). 
 
From the few published examples in the use of HDAC inhibitors in bacterial systems, they been shown to 
improve or reduce the level of production of known natural products and their potential to be used for 
revealing cryptic natural products remains to be demonstrated. Although the exact mechanism of 
biosynthetic pathways induction or repression is not yet fully understood, the use of HDAC inhibitors 
provides a cheap and easy method to screen both bacteria and fungi for the production of secondary 
metabolites.  
 
3.5 Chemical Elicitors 
Sub-inhibitory concentrations (SIC) of antibiotics have been shown to regulate gene expression at a 
transcriptional level, affecting 5-10% of all transcripts.
55
 This effect is observed with concentrations as low 
as 1% of MIC values. 
56,574
 Transcriptomic studies using a combination of microarrays and reporter assays, 
have demonstrated that sub-inhibitory concentrations of antibiotics can activate quorum sensing regulators 
including those belonging to the LuxR family.
55
 Many phenotypic changes have been observed in the 
presence of sub-inhibitory concentrations of antibiotics, including the induction of biofilm formation and 
increased bacterial motility.
58 
SICs of antibiotics are being used as a tool to activate the biosynthesis of 
cryptic natural products. In a marine Streptomyces spp., a novel series of phenazines named 
streptophenazines (31), differing in their alkyl chain, were produced in response to stimulation with SICs of 
either tetracycline (32) or bacitracin (33).
59
 Interestingly, it was found that whilst tetracycline had a positive 
effect on 5 of the 8 phenazines, elevating titres between 2.6 and 10.7-fold, it had a negative impact on 
streptophenazine biosynthesis (31), leading to a decrease in production to 80% of the original titre. Pulse 
feeding with bacitracin (33) at 0.1 μg/ml increased titres of streptophenazine (31) 2.2-fold.59 It is noteworthy 
that the same chemical modulator can have both a stimulatory and inhibitory effect on members of the same 
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family of natural products, with the profile of streptophenazines produced dependent upon which antibiotic 
was being used to elicit their production.
  
A range of polyether antibiotics have also been observed to induce antibiotic production in Streptomyces 
spp.. Promomycin (34), a polyether natural product produced by Streptomyces scabrisporus strain 153, was 
found to induce antibiotic production in a number of environmental isolates when administered at SICs.
60 
 
Other polyethers, salinomycin (35), monensin (36) and nigercin (37) had similar effects, inducing antibiotic 
production in isolated strains when administered at SIC.
60 
 Recently, one of the antibiotics whose production 
was induced by the administration of SICs of monensin to the producing strain, Streptomyces 
griseorubiginosus strain 574, was identified as the isonitrile antibiotic SF2768 (38).
61
 Although not an 
antibiotic, the commercially available siderophore desferrioxamine E (39) produced by a number of 
Streptomyces spp., has been shown to induce and elevate the biosynthesis of some metabolites. The addition 
of 3 μg to a filter disc, creating a diffusion gradient adjacent to an environmental isolate, induced the 
production of an unknown yellow pigment and antibiotic.
62 
Treating cultures with lincomycin (40), which 
alters the transcriptional machinery, was seen to impact secondary metabolite production elevating 
streptomycin (41) production levels in Streptomyces griseus from 40 -100 μg/mL. Lincomycin binds to the 
ribosome of Gram-positive bacteria, and the authors postulate that although regulation of metabolite 
production in actinomycetes is highly complex, modification of the translational apparatus is likely to be key 
to inducing antibiotic production,
63
 further examples of such effects on secondary metabolite production are 
discussed in section 4.1. In a medium throughput approach to looking for small molecule activators, using a 
lacZ fusion reporter assay, Seyedsayamdost explored the effect of sub-inhibitory concentrations of a library 
of 640 small molecules, many of which were clinically utilised antibiotics.  Using the cryptic malleilactone 
(mal) cluster in Burkholderia thailandensis, a genetically tractable strain, as test bed malL essential to the 
biosynthesis of the metabolite was fused to lacZ and used as a reporter. In these studies it was demonstrated 
that low concentrations of the antibiotic trimethoprim (42) resulted in the induction of at least 5 biosynthetic 
gene clusters including mal. The mechanism of upregulation could be due to the elevated transcription of 
malR, an orphan luxR transcriptional regulator that could bind to small molecule elicitors or perhaps, as a 
series of synthetic as well as natural antibiotics elicited upregulation, a stress-induced mechanism could be 
operational.
64
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Figure 10. Streptophenazines (31)
 
,
59
 SF2768 (38) ,
61
 streptomycin (41).
63
 Sub-inhibitory Concentration 
(SIC) stimulants tetracycline (32), bacitracin (33), promomycin (34), salinomycin (35), monensin (36), 
nigercin (37), desferrioxamine E (39), lincomycin (40) and trimethoprim (42). 
 
4. Genetic modification approaches 
Genetic modification of bacterial strains represents an alternative approach to accessing novel biosynthetic 
pathways or improving the titres of known natural products. Approaches range from the technology light and 
non-specific induction of spontaneous mutations within the organism through the use of mutagenic 
compounds or radiation to informed and directed metabolic engineering. 
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4.1  Ribosome engineering and alteration in the transcriptional machinery 
The concept of ribosome engineering in order to elevate or unlock metabolite production was introduced for 
the first time when Shima and coworkers observed that a S. lividans spontaneous mutant, resistant to 
streptomycin, was able to produce the antibiotic actinorhodin (19). This was significant as actinorhodin was 
not produced by the wild type strain. The observed mutation, a substitution of a lysine residue with a 
glutamate residue at position 88 in the ribosomal protein S12 responsible for streptomycin resistance, was 
found to alter translational accuracy (Figure 12A).
65
  
Multiple point mutations, affecting both transcriptional and translational machineries, may arise when 
bacteria are cultured on media containing different antibiotics. High concentrations of antibiotics must be 
used (depending on the bacterium tested, up to 100-fold of MIC values) in order to generate spontaneous 
mutants that overproduce a compound. The frequency of mutation in a microbial population is usually 10
−6–
10
−8
, therefore 10
9 
or more cells must be plated in order to isolate mutant colonies after several days of 
incubation.
66  
These findings have been rationalised in order to select mutants with improved production of 
known compounds or to activate silent gene clusters encoding novel secondary metabolites. Utilising such an 
approach, a S. coelicolor strain known to be resistant to rifampicin, streptomycin and gentamicin, was grown 
in media containing up to eight different antibiotics: mutants were selected by screening for resistance. A 
280-fold increase (1.63 g/L) of actinorhodin (19) production was observed in a clone able to grow in the 
presence of all the tested antibiotics. Sequence analysis of this mutant showed the insertion of a glycine 
residue at position 92 of the ribosomal protein S12 conferring resistance to paromomycin (43); however, 
mutations responsible for resistance to the other antibiotics were not identified.
67
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Figure 11. Paromomycin (43) used at high concentration resulted in a ribosomal mutation giving rise to 
substantial elevation of actinorhodin production in S. coelicolor.  Following a similar approach 
actinolactomycin (44)
 
,
68
 and norvancomycin (47)
 69
 are also produced in higher titre; and rifampicin (45) to 
unlock the production of federicamycin (46) through the ribosomal mutation. 
A similar approach was adopted in which an Actinomycetes strain was cultured in media containing high 
concentrations of streptomycin. This not only resulted in the enhanced production of actinolactomycin (44), 
an anticancer agent, but additional peaks indicating the production of putative novel metabolites were 
observed by HPLC.
68
 Ochi has demonstrated, through generating rifampin resistant mutants of a series of 
actinomycetes, an up to 70-fold increase in the transcription level of biosynthetic gene clusters could be seen, 
with many of the mutants producing metabolites that could not be detected in the parent, wild-type strains. 
Rifampin resistance mutants were observed to develop at a frequency of 10
-7
 -10
-8
; sequencing of these 
mutants showed that all mutations occurred in the rpoB gene encoding the RNAP β-subunit. The team were 
able to demonstrate that this strategy could be successfully applied to seven out of eight actinomycetes test 
bed strains.
70
  Similarly, by culturing the marine bacterium, Streptomyces somaliensis SCS10 ZHH with 300 
μg/mL rifampicin (45), a mutation in the β sububit of RNA polymerase occurred unlocking the production of 
fredericamycin (46), a compound with potent toxicity. Using this approach followed by a response surface 
methodology (RSM) media optimisation, the group were able to go from cluster silence to achieving titres of 
680 mg/L.
71
 This strategy represents an approach to ribosome modification that does not require molecular 
biology, or the ability to transform the strain.  Combinatorial mutations in ribosomal proteins and RNA 
polymerase can also increase secondary metabolite production through, for example, enhancing promoter 
binding (Figure 12B): for example Amycolatopsis orientalis with mutations in both transcriptional and 
 18 
translational machinery showed a 46% increase of in the production of norvancomycin (47)
 
.
69 
 These and 
many other examples illustrate the power of serendipidous and informed ribosome and RNA polymerase 
engineering in increasing titres of known bioactive compounds and for activating cryptic gene clusters for 
the isolation of novel compounds.
72 
 
 
 
 
 
Figure 12. Antibiotic induced spontaneous K88E mutation in the 12S protein of the small ribosomial subunit 
leading to actinorhodin production in S. lividans (A). Rifampicin induced spontaneous mutations in the 
transcriptional machinery enhance the strenght of promoter binding by the RNA polymerase (B). 
 
4.2 Manipulation of pathway-specific and global regulators  
Bacterial secondary metabolism gene clusters are generally transcribed from an inducible promoter under the 
control of regulators, activators and repressors; these modulate the expression of the gene cluster in response 
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to environmental changes. Pathway-specific regulators act on the biosynthetic genes of their respective 
clusters whilst global regulators, are located outside the biosynthetic gene cluster and have a pleiotropic 
effect acting simultaneously on different metabolic pathways involved in various cellular functions. The 
overexpression of activators and silencing of repressors represent straightforward ways to enhance or unlock 
the expression of gene clusters of interest (Figure 13).  
 
Figure 13. Simplified scheme of activator and repressor mediated regulation.  
Gene transcription is silenced by repressors bound to operator sites preventing the RNA polymerase from 
starting the transcription of the gene. By sequestering repressors or down-regulating their production, 
transcription can be activated. The directed transcription of gene clusters can also be achieved by up 
regulating their respective activators, which are able to recruit the RNA polymerase to their promoter site. 
Using the strategy of replacing the natural promoter of a series of gene clusters of interest with a strong 
inducible or constitutive promoter, by employing a cluster expression plasmid pCEP vector containing the 
first 300-600 bp of the biosynthetic cluster, enabling the introduction of the new promoter via homologous 
integration, the Bode group have reported a general tenfold increase in production of bacterial compounds 
including a series GameXPeptides, indigoidine.
73
 They have used this strategy to determine the previously 
unknown products of biosynthetic gene clusters. Through combining this approach with total synthesis and 
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isotopic labelling strategies they have revealed and confirmed the product of the largest continuous bacterial 
NRPS discovered so far, consisting of 15 consecutive modules encoded by the 4.91 kol gene,  and aptly 
named “Kolossin”.74 This formylated peptide is metabolically costly for the producing bacterium 
Photorhabdus luminescents to generate, and the natural mechanisms for activation of this pathway and the 
role of this compound remain to be determined.
74
Salas employs a similar approach, to that utilised by Bode, 
of inserting strong constitutive promoters; in this way he explores five of the twenty seven gene clusters 
bioinformatically predicted in the genome of the common heterologous expression host, Streptomyces 
albus.
75
 Brady and co-workers also adopt the approach of refactoring series of promoters within the natural 
producing organism, developing replacement cassettes for the multiplexed exchange of constitutively active 
promoters in place of all native promoters within silent gene clusters. This approach, employing bidirectional 
promoter cassettes, benefits from using quick homologous recombination of the promoter region within a 
yeast auxotroph followed by its reengineering in to the natural producing strain. In such a manner the group 
used a series of single cassette insertions to replace each of the three natural bidirectional promoter regions 
involved in indolotryptoline biosynthesis with synthetic promoter cassettes, whilst at the same time repairing 
a base deletion in one of the genes that had rendered it non functional; the product of the previously dead 
cluster has been named lazarimide.
76
 
In Streptomycetes, overexpression of the pathway-specific regulators SARP (Antibiotic Regulatory Protein 
family) has been shown to trigger the production of secondary metabolites. The pathway specific regulator 
ccaR, a member of the SARP family, is responsible for the regulation of clavulanic acid (48) in Streptomyces 
clavuligerus.
77
 Overexpression of ccaR in a high copy number vector or integration in the chromosome of 
the strain, resulted in 2.25 and 9.4 fold increase of clavulanic production respectively.
78 
 A further example, 
is the use of the consecutive overexpression of the three regulatory genes sgcR1, sgcR2 and sgcR3 for the 
production of enediyne C-1027 (49). These genes have been identified to belong to the AraC family of 
transcriptional regulators.
79
 Curiously, whilst their overexpression on an individual and consecutive basis 
resulted in increased C-1027 production, overexpression of these regulators in parallel had no noticeable 
effect on production, highlighting the complex interplay between regulators.  
Silencing transcriptional repressors provides another useful means for increasing production. A rather 
innovative and unusual method that has been successfully demonstrated to increase antibiotic production is 
the use of decoy oligonucleotides.
80 
 McArthur and Bibb developed a series of double stranded 
oligonucleotides containing the regulatory element used by the repressor involved in the regulation of 
actinorhodin (23) biosynthesis. These oligonucleotides were engineered so that they formed stable structures 
able to compete for binding of the repressor protein with the regulatory element in the genomic DNA. This 
technology has applicability as either a molecular switch to tune antibiotic production or as a tool with which 
to investigate antibiotic regulators.  
In addition to pathway specific regulators, global regulators play an important role in the initiation of 
production of secondary metabolites since, when activated, they produce a pleiotropic effect ‘switching on’ 
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or ‘off’ numerous metabolic pathways.81  Mutations in the dasR global regulator, belonging to the GntR 
family, was shown to enhance the production of antibiotics up to 4-fold in S. coelicolor;
82 
 more 
interestingly, complete deletion of the dasR unlocked a cryptic gene cluster encoding a type I polyketide 
synthase not observed in the S. coelicolor wild-type strain.
82 
 Despite the great potential for manipulating 
global regulators for the discovery of novel bioactive compounds, this approach is challenging as 
downstream events induced may affect vital cellular functions. 
 
 
Figure 14. Clavulanic acid (48)
77
 accessed through over expression of the regulator cca and enediyne C-
1027 (49)
79
 produced following the consecutive over expression of sgcR1, sgcR2 and sgcR3. 
 
Figure 15. Transcription Factor Decoys. Using Dumbbell oligo-nucleotides, to mimic genetic regulatory 
elements, thereby sequestering transcription factors, preventing them from binding to their regulatory 
element. 
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4.3 Quorum sensing as a tool for the regulation of secondary metabolism 
In the natural environment, bacteria live in multispecies communities and communication using signalling 
molecules is utilised in order to modulate activities of individual cells within the population. Such 
interaction, referred to as quorum sensing (QS), is population-density dependent since signal molecules need 
to reach a threshold level in order to trigger a concerted response.
83
 QS signal molecules are also known as 
“autoinducers” since they activate their own synthesis. Members of the LuxI/ -type protein families are 
commonly distributed among Gram-negative bacteria. It has been well documented that P. aeruginosa 
utilises multiple lux-like QS systems expressed in a hierarchical manner and their activation triggers 
virulence factor and secondary metabolites production, such as pyrocyanin (50) and rhamnolipid (51).
84,85
 
Liu and coworkers demonstrated that the production of the antibiotic pyrrolnitrin (52) is dependent on the 
lux-like QS based signalling in Serratia plymuthica. They observed that insertional mutation in the splI gene 
led to undetectable quantities of antibiotic, but, after complementation with an active copy of the gene, 
pyrrolnitrin (52) production at the wild type level (1.14 mg/ml) was restored.
86 
 In a similar way, Erwinia 
carotovora produces the carbapenem antibiotics (53).
87
 The triggered production of other compounds 
including fosfomycin (54),
88 
 geldanamycin (55),
89
 pimaricin (56
 90 
pikromycin (57),
91
rapamycin (6)
92
 and 
stambomycin (58)
93
 (encoded by one of the largest known polyketide clusters, spaning ~150 kbp) and many 
more, through the manipulation of lux-like systems is a popular approach showing that the production of 
natural products in bacterial strains can often be readily manipulated by engineering the promoters under the 
control of QS signal molecules.  Although in most of the cases QS signalling has a positive effect for the 
production of secondary metabolites, in B. thailandensis the genetic manipulation of the luxR homologue 
thaA and the corresponding transcription factor binding region resulted in the activation of an NRPS/PKS 
hybrid gene cluster and production of its corresponding product, thailandamide A (59) whilst in the wild type 
strain, thailandamide A (59) biosynthesis was not observed except in low titres during early growth phase.
94 
 
This indicates that for thailandamide A biosynthesis, the complex ThaA/Acylated Homoserine Lactone 
(AHL) is acting as a negative regulator.  
In a recent study to unlock a cryptic biosynthetic cluster encoding novel naphthalenic octaketide ansamycins, 
Shen and co-workers firstly investigated the introduction of the strong consitutive promoter ermE* (in a 
strategy similar to that reported by Bode in 4.2), this resulted in partial activation of the pathway with an 
increase in the transcriptional levels of only two of the genes. Analysis of the biosynthetic cluster indicated 
that a putative positive regulator of the LuxR family of transcription factors was encoded, nam1.  Upon 
constitutive over-expressing of nam1 by placing it under the control of the ermE* promoter, a 12-30% 
increase in the levels of transcription of all of the genes within the biosynthetic pathway could be seen, and 
the encoded natural products produced in quantities sufficient for characterisation.
95
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Figure 16. Pyrocyanin (50),
84
 rhamnolipid (51),
85
 pyrrolnitrin (52),
86
 carbapenem antibiotics (53). The 
production of compounds including fosfomycin (54),
88 
geldanamycin (55),
89 
 pimaricin (56),
90
 pikromycin 
(57), stambomycin (58) and thailandamide A (59) 
94
 has been successfully triggered through QS 
manipulation.  γ-Butyrolactone (GBL).  
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In a similar fashion to AHL-mediated quorum sensing in Gram-negative bacteria, γ-butyrolactone (GBL) 
sensing in the Gram-positive Streptomycetes is well documented, with these acylated lactones being 
structurally similar to AHLs.
96 
 Streptomyces spp. are therefore considered unusual amongst Gram-positive 
bacteria as most Gram-positive bacteria utilise peptide signalling based on two component systems.
97 
 Just as 
with AHL’s in Gram-negative bacteria, GBLs have been demonstrated to play an important role in regulating 
secondary metabolite production. 
Amongst the 14 cryptic biosynthetic clusters identified in S. coelicolor, is a putative polyketide biosynthetic 
cluster named Cryptic Polyketide (cpk). Within this gene cluster resides a GBL receptor ScbR2, which acts 
as a transcriptional repressor.
98
 Gottelt et al. created a scbR2 knock out which resulted in a mutant capable of 
producing two novel metabolites: Yellow Cryptic Polyketide (yCPK) and Antibiotic Cryptic Polyketide 
(abCPK).
98  
The yellow metabolite, named coelimycin (60), was subsequently  structurally characterised by 
Challis and co-workers.
99
 
 
Except for the well-studied GBL, new signalling molecules have been reported and used to activate cryptic 
gene clusters. Corre and coworkers discovered a family of 5 new 2-alkyl-4-hydroxymethylfuran-3-
carboxylic acids (AHFCAs), exemplified as methylenomycin furans (MMF), which are the products of the 
mmfR-mmfLHP-mmyR genes, could induce the production of methylenomycin (61) in S. coelicolor.
100
  
Genes homologous to mmfLHP were found in Streptomyces venezuelae ATCC 10712 by BLAST searches. 
Inactivation of the mmyR homologue gbnR induced production of novel metabolites, named gaburedins 
(62).
101
 Avenolide, (4S, 10R)-10-hydroxy-10-methyl-9-oxo-dodec-2-en-1,4-olide, triggered avermectin (63) 
production at nanomolar concentrations in Streptomyces avermitilis.
102
 Similarly, two butenolide signalling 
molecules SRB1 and SRB2 induced lankacidin (64) and lankamycin (65) production in Streptomyces 
rochei.
103
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Figure 17. Coelimycin P1 (60), mythylenomycin A (61), gaburedin (62), avermectins (63), lankacidins(64) 
and lankamycin (65). 
5. Heterologous Expression  
The heterologous expression of genes encoding the biosynthesis of bioactive compounds in an “unnatural 
host” can prove challenging: hurdles of transcription and translation in the foreign host must first be 
overcome, enzymes must be correctly folded and may require post-transcriptional modifications crucial for 
their function within the biosynthetic pathway. However, increasingly, the heterologous expression of 
biosynthetic pathways and generation of the natural product is becoming an established approach to confirm 
that a biosynthetic gene cluster is responsible for the biogenesis of a particular metabolite of interest.
104,105
 
Series of useful, engineered heterologous expression hosts are available,
106-108
 and this approach is also 
becoming a mainstream method through which to unlock silent or cryptic gene clusters that have been 
identified by genome mining and this has been summarized in a recent reviews of heterologous expression of 
bacterial natural products
109
. Heterologous expression also represents a powerful tool for the discovery of 
novel compounds through cloning of DNA from metagenomic libraries.
110,111
 Metagenomic investigations by 
Piel on uncultured/unculturable sponge associated organisms provide evidence, for the first time, that a 
single member of the Theonella swinhoei microbiome community is the source of almost all of the 
polyketide and peptide metabolites isolated from the sponge host.
112 
Heterologous expression of genes from 
this member, named E. factor TSY1 may enable rapid access to this rich chemistry. 
 
A straightforward approach for heterologous expression is to clone clusters of interest under inducible 
promoters (this is a complementary approach to the introduction of strong constitutive promoters into the 
wild type producing organism). However, this requires detailed information of the target gene cluster, codon 
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and substrate usage and is perhaps the most labour-intense approach described in this review. PKS and NRPs 
megasynthases are usually encoded by gene clusters that can reach over 100 Kb in length. For example, the 
gene cluster encoding the antifungal nystatin is 125 Kb in length.
113 
 Cloning such large clusters is not 
without challenge, often even with a modest 30 Kb cluster, a degree of luck is required for the entire cluster 
to be found included within a single cosmid. Frequently the cluster can be split between several cosmids 
which then require ‘stitching’ together. Many successful examples exist as previously reviewed.109 For 
example Bian et al. demonstrated the activation of a cryptic biosynthetic gene cluster by heterologous 
expression, successfully expressing an 18 Kb cryptic luminmycin biosynthetic pathway from Photorhabdus 
luminescens in E. coli.
114
 From a 12 L culture of the heterologous expression system, 3.0 mg luminmycin A 
(66), 0.5 mg luminmycin B (67) and 0.4 mg luminmycin C (68) were isolated; luminmycin A (66) had not 
been detected in the original extract from P. luminescens. Further engineering is often required in the 
heterologous host in order to unlock the silent or cryptic biosynthesis pathways; for example the replacement 
of promoters native to the pathway with stronger ones. Promoter selection is determined by the choice of 
expression host actI/actIII and ermE in Streptomyces spp. and Pm in Pseudomonas spp..
115
   Body provides 
an excellent and detailed review regarding the harnessing of transcription for unlocking cryptic gene clusters 
and places particular emphasis on promoter engineering.
115
 Utilising such an approach Luo et al. 
reconstructed an entire cryptic gene cluster from Streptomyces griseus in S. lividans by inserting optimized 
promoters upstream of the genes.
116
 The authors demonstrated the transcription of the gene cluster in the 
heterologous host resulting in the production of two polycyclic tetramate macrolactam compounds, not seen 
in the native host, alteramide A (69) and a novel tetramate (70). Apart from promoter optimization in 
heterologous expression systems, in many cases, regulatory genes need to be engineered (overexpression of 
upregulators ones, and deletion of down regulators). One such example is the heterologous expression study 
by Yamanaka et al. By genome reading the authors found a 67 Kb NRPS biosynthetic gene cluster, predicted 
to produce a novel lipopeptide, in the marine actinomycete Saccharomonospora sp. CNQ-490. No such 
lipopeptide was identified in the native strain.
117
 After heterologous expression of the engineered gene 
cluster with deletion of a LuxR-type negative transcriptional regulator in S. coelicolor, 4 L of fermentation 
broth was reported to have yielded ~60mg of a series of at least 8 closely related lipopeptides; from this 
mixture 4 mg taromycin A (71), a novel lipopeptide was purified. The rapid and direct in vitro cloning of the 
41 kbp gene cluster encoding conglobactin, and its subsequent heterologous expression, exemplifies a 
particularly expeditious and promising approach.
117b
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Figure 18. Luminmycin A-C (66-68) isolated through heterologous expression studies in E. coli, 0.5 mg 
luminmycin B (67) and 0.4 mg luminmycin C (68) were isolated; luminmycin A (66) had not been detected 
in the original extract from the natural host P. luminescens.
 114
 Alteramide A (69) and a novel tetramate (70) 
accessed through heterologous expression and promoter engineering in S. lividans.
116
 Heterologous 
expression of a gene cluster from marine actinomycete Saccharomonospora sp. CNQ-490 into S. coelicolor 
accompanied by deletion of a LuxR-type negative transcriptional regulator in S. coelicolor, results in 
taromycin A (71) production.
117
 
 
Summary 
Today, in the light of data from the many recently sequenced microbes and metagenomic libraries, we are 
even more aware of the wealth of untapped biosynthetic potential that exists. These data imply that, in terms 
of bioactive metabolite isolation and identification, so far only the very tip of the iceberg has been scraped 
and numerous valuable natural products remain to be discovered. These are exciting times, with new 
approaches to unlocking the treasures of previously uncultivable bacteria being explored and the discovery 
of  teixobactin, a new antibiotic to which there was no detectable resistance.
118
  
Here we provide, in one place, an overview and guide of all of the main approaches available for unlocking 
and harnessing this biosynthetic potential of bacteria and revealing or increasing production of these 
previously unexplored bacterial natural products. Approaches overviewed range from easily accessible, low-
 28 
tech and low-cost methods such as media manipulation and co-culturing, which can be strikingly effective, 
to the more focused and demanding molecular biological strategies of engineering organisms to produce a 
specific product. Unsurprisingly there is no single approach that can be used reliably to unlock every cryptic 
pathway. 
 
Advances in genome annotation software are making it increasingly easy for natural products encoded by 
bacterial genomes to be predicted, providing a valuable tool for the identification of novel natural products. 
Yet in silico prediction only works faultlessly for highly canonical natural products.  Currently information 
relating to biosynthetic clusters is distributed through the literature, and there is a call for the systematic 
deposition of such data to enable greater ease of retrieval and improved mining of sequence data.
119
 There is 
still much to be learnt about fundamentals of biosynthesis and for biosynthetically unprecedented assemblies 
in silico predictions are not possible. Heterologous expression provides a useful, but sometimes challenging 
approach to enable the production of a single series of compounds from a cryptic cluster of interest thereby 
enabling the compound’s identification; such an approach represents the only way for accessing the chemical 
pallet of unculturable microbes. Metabolic switching in actinomycetes and the regulation of secondary 
metabolite production is highly complex and varied
120-122
 and such expression systems often require careful 
tailoring in order to enable production of a specific compound of interest; this can often be a bottle-neck to 
the discovery process.  
Recent studies show that bacterial cross talk and the specific activation of certain biosynthetic pathways is 
far more complex than we had previously appreciated, and there is much research to be carried out before we 
can rationally utilise this powerful language. Rewards in the discovery of novel bioactive natural products 
are likely to be high. Recent reviews in this area have been published.
123, 124
 Over the past 5 years due to 
genome sequencing and advances in molecular biological and analytical tools there has been a striking re-
invigoration of natural product research. The relatively recent area of unlocking cryptics is advancing at an 
impressive rate enabling access to previously unidentified compounds.   
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